Related Experiment Videos
[Pneumocystis carinii pneumonia in HIV-negative immunosuppressed patients]
1Departement für Innere Medizin, Medizinische Klinik, Universitätsspital Zürich.
Abstract:
During a period of 10 years 129 immunosuppressed HIV-negative patients were evaluated for pulmonary complications. A definite diagnosis could be established in 72 cases (56%): Pneumocystis carinii pneumonia (PCP) (25), pulmonary involvement of underlying disease (10), drug toxicity (8), mycobacterioses (6), bacterial pneumonias (5), aspergillosis (5), others (13). The underlying conditions in patients with PCP were: lymphatic neoplasias (11), immunosuppression after solid organ (9) and after bone marrow transplantation (3), cytotoxic therapy for lupus erythematodes (1) and carcinoma (1). In 8 of 9 transplant patients anti-rejection therapy preceded the episode of PCP. Six patients (24%) died from respiratory failure 1 to 25 days after diagnosis of PCP, despite mechanical ventilation in four. Two patients recovered completely after mechanical ventilation for 14 and 30 days respectively. The frequency of PCP has markedly increased during the last few years: 1981-1987: 2 cases (6%), 1988: 4 (14%), 1989: 8 (42%) and 1990: 11 (26%). This can hardly be explained by improved diagnostic sensitivity or an increased number of immunosuppressed patients. Apart from the use of more potent immunosuppressive agents, the increased prevalence of Pneumocystis carinii may play an important role.
Insights
Pulmonary complications in immunosuppressed patients are common. Pneumocystis pneumonia (PCP) frequency increased significantly, possibly due to potent immunosuppressants and higher Pneumocystis carinii prevalence.
Area of Science:
- Pulmonology
- Infectious Diseases
- Immunology
Context:
- 129 immunosuppressed, HIV-negative patients were evaluated over 10 years for pulmonary complications.
- Pulmonary complications represent a significant challenge in managing immunosuppressed patient populations.
- Identifying the specific causes of pulmonary issues is crucial for effective treatment and patient outcomes.
Purpose:
- To investigate the spectrum of pulmonary complications in immunosuppressed, HIV-negative patients.
- To determine the incidence and causes of pulmonary issues, with a focus on Pneumocystis pneumonia (PCP).
- To analyze trends in PCP frequency and potential contributing factors.
Summary:
- A definite diagnosis was established in 56% of patients, with Pneumocystis pneumonia (PCP) being the most frequent diagnosis (25 cases).
- Underlying conditions for PCP included lymphatic neoplasias and immunosuppression post-transplantation, often preceded by anti-rejection therapy.
- A marked increase in PCP frequency was observed, suggesting factors beyond diagnostic improvements, potentially including potent immunosuppressive agents and increased Pneumocystis carinii prevalence.
Impact:
- PCP diagnosis carried a significant mortality risk, with 24% of patients dying from respiratory failure despite intensive care.
- The study highlights the rising incidence of PCP in immunosuppressed individuals, necessitating a re-evaluation of preventative and therapeutic strategies.
- Findings underscore the importance of considering PCP in the differential diagnosis of pulmonary complications in this vulnerable patient group.